Navigation Links
GENova files patent for new breast cancer treatment
Date:9/10/2009

NEW YORK, NY, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has filed a patent for a potential blockbuster drug target that combats breast cancer.

The target, Tetanolic acid, is a tailor-made lipid which induces cell death in breast cancer cells, thus curtailing development of the harmful cancer.

This novel approach - using proteins to stop cancer - is based on recent discoveries that indicate that most tumors are derived from a cancer stem cell. The technology behind Tetanolic acid involved identifying specific characteristics of these cancer stem cells and then tailoring a lipid (Tetanolic acid) that can identify these characteristics and then attack the malignant cells whilst leaving healthy cells intact. This tailor-made cancer treatment strategy is far superior to any existing therapies, as it terminates the cancer at the source, with no side effects, and no harm to surrounding healthy tissues.

"This target has tremendous market potential, as it can ultimately eliminate the need for surgery and chemotherapy," says Aaron Whiteman for GENova.

Worldwide, breast cancer is the fifth most common cause of cancer death, and is the most common cancer (and cause of cancer death) in women. The demand for new and better treatments for the disease is as urgent as ever.

Whiteman explains GENova's novel approach: "If you compared this disease to a tree, so far, treatments have only treated the crown of the tree - its branches and leaves, and even tried to hit the stem, but no treatment has penetrated its roots. Now that we can identify cancer stem cells, we can remove the root at its formation, and therefore eliminate all sources of life to the tumor. That is the potential behind Tetonolic acid."

About GENova B
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. GENova appoints Director of Asian business development
2. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
3. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
4. Genova files patent for new prostate cancer treatment
5. GENova names Dr. John Savin as Vice President
6. GENova names Aaron Whiteman as CEO
7. Longevinex(R) Files Lawsuit Against ResveratrolBenefits.com, for False and Misleading Statements
8. US Farms, Inc. Files Trademark Application for Aloe365
9. Sun Pharmaceutical Files HSR Application for Taro Tender Offer
10. InfoLogix Files Preliminary Proxy Statement in Connection with Special Meeting of Its Stockholders to Approve Recapitalization Plan
11. VirtualHealth Technologies Files 8k Related to the August 17th Announcement of Private Access Payment and Document Modification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Chrysler made news recently when it refused ... million Jeeps. The Jeep models in question are the 1993-2004 ... to the NHTSA are vulnerable to fire and explosion in ... are rear-mounted and have been alleged to catch fire or ... Cherokee with 32 rear-end crashes, which resulted in 44 deaths ...
(Date:6/19/2013)... Amber Roberson with the Robert ... Native Care Health, LLC and Medcase, LLC, became ... (NAHU) new professional development course on the Patient ... education course for agents has been approved in ... education credits from the Missouri Department of Insurance. ...
(Date:6/19/2013)... June 19, 2013 As Januvia ... continue to mount in courts throughout the U.S., Bernstein ... Administration (FDA) recently held a meeting to discuss the ... incretin mimetics. According to a June 12th report ... the makers of Januvia and similar drugs, following a ...
(Date:6/19/2013)... Lawrence, KS (PRWEB) June 19, 2013 ... photographs is common with today’s computer software, it creates ... a form of misconduct. As an already published case ... of photo manipulation. , The Journal of Parasitology ... image manipulation in a 2004 article published in ...
(Date:6/19/2013)... by researchers at The University of Texas MD Anderson ... remarkable promise for the treatment of relapsed or refractory ... findings of the 18-center Phase 2 study were published ... . Previous interim findings were presented in December 2012 ... and Exposition. , Unprecedented results, fewer side ...
Breaking Medicine News(10 mins):Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 2Health News:Zinda & Davis PLLC: Why the Chrysler Recall Refusal Matters And May Set a Dangerous Precedent 3Health News:RWI Benefits, LLC Becomes PPACA Certified 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 2Health News:Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics 3Health News:Altered Photo in Journal Article Illustrates the Need for Manipulation Guidelines 2Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2
... in Comprehensive Report Comparing SSO and ... Healthcare Industry, ANDOVER, Mass., March 19 ... Sign-On (SSO), announced today that it ranked ... comparing SSO and,context management vendors performance. The ...
... in German . , Transport processes in ... on the roads. Molecular motors, which are special protein molecules, ... and transport it along microtubules, which are the roads of ... smaller than trucks and can only move as far as ...
... 19 To develop new strategies to control tuberculosis ... worlds population and kills almost two million people every ... has received an $11.4 million grant from the Bill ... researchers to use new imaging technologies to study TB ...
... 19 Mirion Technologies, the,leading global provider of ... industry, will showcase two new products at the,10th ... from,March 25th - 28th., Mirion,s Health Physics ... Contamination Monitor. The TwoStep Exit monitor is a,new ...
... be at the forefront of fighting cancer thanks to ... Research Foundation (ACRF). , The ACRF funding will ... and Metabolic Medicine (DI), and their partners from the ... tools to help them discover genes linked to cancer. ...
... are more respectful, SAN DIEGO, March 19 Over ... one to three years, find a non-nursing,job, work part-time, or ... by AMN Healthcare, the largest health care staffing firm in,the ... many baby,boomer nurses may be facing career burn-out. About 46 ...
Cached Medicine News:Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 2Health News:Sentillion Ranked #1 Vendor in KLAS' Single Sign-On & Context Management Report 3Health News:Tug of war in the cells 2Health News:Tug of war in the cells 3Health News:Stopping a deadly killer 2Health News:Mirion Technologies to Showcase New Product Offerings for the Nuclear Industry During 10th Annual China International Nuclear Industry Exhibition 2Health News:Survey: 35% of Baby Boomer Nurses Plan a Career Change in the Next One to Three Years 2
(Date:6/19/2013)... , June 19, 2013 Eli Lilly and ... alert about two illegal scams, purportedly using the name ... that are actively targeting the public through postal mail ... have no connection to any foreign lottery organizations and ... by the job-seeking victims of the scam. The activities ...
(Date:6/19/2013)... YORK , June 19, 2013 ... that a new market research report ... Partnerships, Licensing, Investments and ... 2013 in Pharmaceuticals http://www.reportlinker.com/p0925641/Partnerships-Licensing-Investments-and-MA-Deals-and-Trends-for-May-2013-in-Pharmaceuticals.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Investment_Banking ... Investments and M&A Deals and Trends ...
(Date:6/19/2013)... 2013 Ellen MacArthur Foundation ... tre åren kommer att vara en partner för ... ekonomi. Efter stiftelsens framgångsrika partnerskap med ... kommer Philips att ansluta sig som partner för ... sin egen verksamhet och stödja stiftelsens arbete inom ...
Breaking Medicine Technology:Lilly Issues Alert for Illegal Scams Involving Fraudulent Checks and Online Job Requests 2Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 2Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 3Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 4Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 5Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 6Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 7Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 8Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 9Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 10Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 11Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 12Partnerships, Licensing, Investments and M&A Deals and Trends for May 2013 in Pharmaceuticals 13Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 2Ellen MacArthur Foundation presenterar Philips som global partner vid det konstituerande internationella toppmötet om cirkulär ekonomi 3
... NewCardio, Inc., (OTC Bulletin Board: NWCI ... the Company has been invited to present the results ... upcoming conference entitled "Cardiovascular Safety in Drug Development: State-of-the-Art ... (FDA), the Cardiac Safety Research Consortium (CSRC) and the ...
... ICU Medical, Inc. (Nasdaq: ICUI ) ... release of the MicroCLAVE Clear Neutral Displacement Needlefree Connector ... Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas. ... verifying effective flushing of the patient catheter after use ...
Cached Medicine Technology:NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 2NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 3NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 4NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 5NewCardio Invited to Present Latest QTinno Performance Improvements at FDA-Sponsored Conference on Cardiovascular Safety in Drug Development 6ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas 2ICU Medical to Launch MicroCLAVE® Clear Needlefree Connector at the Annual Scientific Meeting of the Society for Healthcare Epidemiology of America (SHEA) April 1-4 in Dallas 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: